| 144 | 0 | 40 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 研究肥厚型心肌病(HCM)合并肺动脉高压(PH)患者发生不良预后的危险因素。方法 选取确诊为HCM的患者(n=154),根据是否合并PH将患者分为对照组(n=119)与病例组(n=35),并对比分析基线及超声心动图资料；再将病例组患者根据肺动脉收缩压(PASP)升高程度分为PH 1组(n=25)及PH 2组(n=10)。对患者进行随访并记录2年内是否发生不良事件，运用Cox回归分析HCM合并PH的患者发生不良预后的危险因素，绘制KM生存曲线进行HCM合并PH患者生存风险分析。结果 HCM患者的PH患病率22.73%,与对照组相比，女性(48.57%)及合并心律失常(42.86%)的患者在病例组中占比较大(P<0.01)。对病例组患者进行斯皮尔曼相关性分析提示女性、中重度瓣膜反流与PASP的变化正相关，心房内径、左房室耦联指数、左室质量分数及二尖瓣舒张早期血流速度峰值(E)与二尖瓣环根部舒张早期心肌运动速度峰值(e′)(E/e′)值均可随PASP水平的升高而增加(P<0.05),左室射血分数随PASP水平的增加而降低(P<0.001)。HCM患者不良事件发生率为25.97%,Log Rank检验提示PH 1组与PH 2组患者累计生存率组间差异有统计学意义(P<0.001),Cox回归分析提示，PASP(HR=1.123,95%CI:1.033～1.221)及E/e′值(HR=1.131,95%CI:1.054～1.213)均为合并PH的HCM患者2年内发生不良事件的独立危险因素(P<0.05)。结论 PASP水平及E/e′值均为HCM合并PH患者发生不良预后的独立危险因素。
Abstract：Objective To study the risk factors of poor prognosis in patients with hypertrophic cardiomyopathy(HCM) complicated with pulmonary hypertension(PH).Methods Patients(n=154) diagnosed with HCM were selected.According to whether they were complicated with pH,the patients were divided into control group(n=119 cases) and case group(n=35 cases),and the baseline and echocardiographic data were compared and analyzed.Then the patients in the case group were divided into PH 1 group(n=25 cases) and PH 2 group(n=10cases) according to the degree of elevation of pulmonary artery systolic pressure(PASP).The patients were followed up and recorded whether the patients had adverse events within 2 years.Cox regression analysis was used to analyze the risk factors of poor prognosis in patients with HCM with PH.KM survival curves were plotted for the survival risk analysis of patients with HCM complicated with PH.Results The prevalence of pH in HCM patients was 22.73%.Compared with the control group,women(48.57%) and patients with arrhythmia(42.86%) accounted for a larger proportion in the case group(P <0.01).Spearman correlation analysis of the patients in the case group showed that female,moderate and severe valve regurgitation were positively correlated with the changes of PASP.Atrial diameter,LACI,left ventricular mass fraction and E/e' value all increased with the increase of PASP level(P <0.05),and LVEF decreased with the increase of PASP level(P <0.001).The incidence of adverse events in HCM patients was 25.97%.Log Rank test showed that there was a statistically significant difference in the cumulative survival rate between PH 1 group and PH 2 group(P <0.001).Cox regression analysis showed that PASP(HR=1.123,95% CI=1.033-1.221) and E/e'(HR=1.131,95% CI=1.054-1.213) were independent risk factors for adverse events in HCM patients with PH within 2 years(P <0.05).Conclusion Both PASP levels and E/e' values are independent risk factors for developing poor prognosis in patients of HCM with PH.
[1] Ommen S R,Mital S,Burke M A,et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J].Circulation,2020,142(25):e558-631.doi:10.1161/cir.0000000000000937.
[2] Sugiura K,Kubo T,Ochi Y,et al.Very long-term prognosis in patients with hypertrophic cardiomyopathy:a longitudinal study with a period of 20 years[J].ESC Heart Fail,2022,9(4):2618-25.doi:10.1002/ehf2.13983.
[3] Jin Q,Chen D,Zhang X,et al.Medical management of pulmonary arterial hypertension:current approaches and investigational drugs[J].Pharmaceutics,2023,15(6):1579.doi:10.3390/pharmaceutics15061579.
[4] Writing Committee Members,Ommen S R,Mital S,et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J].J Thorac Cardiovasc Surg,2021,162(1):e23-106.doi:10.1016/j.jtcvs.2021.04.001.
[5] Held M,Wilkens H.Pulmonary hypertension-the new ESC guideline[J].Dtsch Med Wochenschr,2023,148(22):1448-55.doi:10.1055/a-1966-9703.
[6] Santulli G,Wang X,Mone P.Updated ACC/AHA/HFSA 2022 guidelines on heart failure:what is new from epidemiology to clinical management[J].Eur Heart J Cardiovasc Pharmacother,2022,8(5):e23-4.doi:10.1093/ehjcvp/pvac029.
[7] 王华，李莹莹.2022年AHA/ACC/HFSA心力衰竭管理指南解读——从新指南看心衰分类和诊断评估[J].中国心血管病研究，2022,20(6):481-6.doi:10.3969/j.issn.1672-5301.2022.06.001.[7] Wang H,Li Y Y.2022 AHA/ACC/HFSA heart failure management guidelines Interpretations—classification and diagnostic evaluation of heart failure[J].Chin J Cardiovasc Res,2022,20(6):481-6.doi:10.3969/j.issn.1672-5301.2022.06.001.
[8] Toste A.Advances in hypertrophic cardiomyopathy:what the cardiologist needs to know[J].Portuguese J Cardiol,2022,41(6):499-509.doi:10.1016/j.repc.2021.05.015.
[9] Lopes L R,Losi M A,Sheikh N,et al.Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry[J].Eur Heart J Qual Care Clin Outcomes,2022,9(1):42-53.doi:10.1093/ehjqcco/qcac006.
[10] Mielczarek S,Syska P,Lewandowski M,et al.Long-term mortality and risk factor analysis in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillators[J].Pol Arch Intern Med,2022,132(2):16206.doi:10.20452/pamw.16206.
[11] 伍熙，崔颢，肖明虎，等.梗阻性肥厚型心肌病患者发生肺高血压的病例对照研究[J].中华心血管病杂志，2016,44(12):1010-4.doi:10.3760/cma.j.issn.0253-3758.2016.12.004.[11] Wu X,Cui H,Xiao M H,et al.Prevalence of pulmonary hypertension in patients with hypertrophic obstructive cardiomyopathy:a case-control study[J].Chin J Cardiol,2016,44(12):1010-4.doi:10.3760/cma.j.issn.0253-3758.2016.12.004.
[12] Dominguez F,Sanz-Sánchez J,García-Pavía P,et al.Follow-up and prognosis of HCM[J].Glob Cardiol Sci Pract,2018,2018(3):33.doi:10.21542/gcsp.2018.33.
[13] 程子超，李海威，彭红玉，等.射血分数保留型心力衰竭相关性肺动脉高压研究进展[J].中国医药，2023,18(1):119-22.doi:10.3760/j.issn.1673-4777.2023.01.028.[13] Cheng Z C,Li H W,Peng H Y,et al.Research progress of heart failure with preserved ejection fraction associated pulmonary hypertension[J].China Med,2023,18(1):119-22.doi:10.3760/j.issn.1673-4777.2023.01.028.
[14] Kwon S,Kim H K,Kim B,et al.Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy[J].Sci Rep,2022,12(1):6386.doi:10.1038/s41598-022-10389-4.
[15] Nie C,Zhu C,Xiao M,et al.Risk factors of pulmonary arterial hypertension and its relationship with atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy[J].Front Cardiovasc Med,2021,8:666431.doi:10.3389/fcvm.2021.666431.
基本信息:
DOI：10.19405/j.cnki.issn1000-1492.2025.02.024
中图分类号:R542.2;R544.1
引用信息:
[1]娜孜拉·努尔兰,唐雍淇,艾尼娃尔·艾克木等.合并肺动脉高压的肥厚型心肌病患者发生不良预后的危险因素[J].安徽医科大学学报,2025,60(02):351-357.DOI:10.19405/j.cnki.issn1000-1492.2025.02.024.
基金信息:
国家自然科学基金(编号：81660695); 天山创新团队计划(编号：2020D14032)~~